ReviewBiochimica et biophysica acta. Molecular basis of disease2019
Animal models of cholangiocarcinoma.
Review in Biochimica et biophysica acta. Molecular basis of disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance.Nature reviews. Gastroenterology & hepatology · 2023Guideline
- Arid1a deficiency promotes hepatocyte hyperpolyploidy and drives intrahepatic cholangiocarcinoma in mice.Hepatology (Baltimore, Md.) · 2026Article
- How to efficiently establish animal models of cholangiocarcinoma: challenges and inspiration.Medical review (2021) · 2026Review
- Preclinical development of mesothelin-targeting CAR T cells for the treatment of cholangiocarcinoma.Hepatology communications · 2026Article
- Article
- Distinct phenotypic consequences of cholangiocarcinoma-associated FGFR2 alterations depend on biliary epithelial cell state.bioRxiv : the preprint server for biology · 2025Article
- Patient-derived tumor xenograft animal model of gastric cancer in precision chemotherapy.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Diagnostic Approach and Pathological Characterization of Metastatic Intrahepatic Cholangiocarcinoma in a Captive Puma (Animals : an open access journal from MDPI · 2025Article
- Review
- Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Exploring the effects of gut microbiota on cholangiocarcinoma progression by patient-derived organoids.Journal of translational medicine · 2025Review
- Targeting the tumor microenvironment in cholangiocarcinoma to improve immune checkpoint blockade: potential strategies and translational pre-clinical models.Clinical & translational immunology · 2025Review
- The Pivotal Role of Preclinical Animal Models in Anti-Cancer Drug Discovery and Personalized Cancer Therapy Strategies.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Article
- Interventional Radiology Locoregional Therapies for Intrahepatic Cholangiocarcinoma.Life (Basel, Switzerland) · 2024Review
- Inflammatory responses toOpen veterinary journal · 2024Article
- A rat model of cirrhosis with well-differentiated hepatocellular carcinoma induced by thioacetamide.Frontiers in gastroenterology (Lausanne, Switzerland) · 2024Article
- The utilisation of biliary organoids for biomedical applications.Frontiers in bioengineering and biotechnology · 2024Review
- Oncogene-Driven Induction of Orthotopic Cholangiocarcinoma in Mice.Methods in molecular biology (Clifton, N.J.) · 2024Article
- New and Old Key Players in Liver Cancer.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Cholangiocarcinoma (CCA) is an aggressive biliary tract malignancy with a poor overall prognosis. There is a critical need to develop effective targeted therapies for the treatment of this lethal disease. In an effort to address this challenge, preclinical in vivo studies have become paramount in understanding CCA carcinogenesis, progression, and therapy. Various CCA animal models exist including carcinogen-based models in which animals develop CCA after exposure to a carcinogen, genetically engineered mouse models in which genetic changes are induced in mice leading to CCA, murine syngeneic orthotopic models, as well as xenograft tumors derived from xenotransplantation of CCA cells, organoids, and patient-derived tissue. Each type has distinct advantages as well as shortcomings. In the ideal animal model of CCA, the tumor arises from the biliary tract in an immunocompetent host with a species-matched tumor microenvironment. Such a model would also be time-efficient, recapitulate the genetic and histopathological features of human CCA, and predict therapeutic response in humans. Recently developed biliary tract transduction and orthotopic syngeneic transplant mouse models encompass several of these elements. Herein, we review the different animal models of CCA, their advantages and deficiencies, as well as features which mimic human CCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.